Repligen Corp.
(NASDAQ : RGEN)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Like Small Cap Stocks < $20?
You should, we just banked a 30% winner in 2 days!
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
JNJJohnson & Johnson -0.84%166.170.7%$1113.67m
PFEPfizer Inc. -1.73%48.420.9%$897.84m
LLYEli Lilly & Co. -0.46%315.351.1%$807.10m
MRKMerck & Co., Inc. -0.05%91.000.7%$787.49m
ABBVAbbVie, Inc. -0.81%140.291.9%$785.78m
BMYBristol-Myers Squibb Co. -0.98%73.831.0%$632.35m
SIGASIGA Technologies, Inc. -6.38%23.190.0%$437.14m
AZNAstraZeneca Plc -0.34%66.201.0%$362.85m
GBTGlobal Blood Therapeutics, Inc. 0.13%67.095.6%$345.26m
GSKGSK Plc -1.13%33.920.3%$285.63m
ALNYAlnylam Pharmaceuticals, Inc. -0.19%222.718.2%$269.54m
HZNPHorizon Therapeutics Plc -1.81%60.615.4%$218.06m
CCXIChemoCentryx, Inc. 0.22%50.892.9%$208.84m
KRTXKaruna Therapeutics, Inc. 0.03%261.310.0%$204.30m
VERUVeru, Inc. -20.12%19.000.0%$194.94m

Company Profile

Repligen Corp. provides bioprocessing technologies and solutions used in the process of manufacturing biologic drugs. It serves through the following product lines: Chromatography, Filtration, Process Analytics, and Proteins. The Chromatography product includes a range of products used in the downstream purification and quality control of biological drugs. The Filtration products offer a number of advantages to manufacturers of biologic drugs at volumes that span from pilot studies to clinical and commercial-scale production. The Process Analytics products complement and support filtration, chromatography and proteins in-line absorbance measurements allowing for the determination of protein concentration in filtration, chromatography formulation and fill-finish applications. The Proteins product franchise is represented by Protein A affinity ligands, which are a critical component of Protein A chromatography resins used in downstream purification of virtually all mAb-based drugs on the market. The company was founded by Alexander G. Rich and Paul R. Schimmel in May 1981 and is headquartered in Waltham, MA.